Phathom Pharmaceuticals is developing a next-generation stomach acid reducer that would represent the first new mechanism of action in the space in 30 years. Phathom's drug, vonoprazan, has ...

--Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the U.S. commercial ...

Phathom Pharmaceuticals Inc. made recent headway with its new mechanism of action in gastroesophageal reflux disease (GERD) even as further, disturbing discoveries in the space are seeing daylight.

The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial.

A triple therapy of vonoprazan, amoxicillin and bismuth potassium citrate achieved an eradication rate of just over 90%, similar to that of the standard quadruple therapy, in patients with ...

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD ...

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032 Provided by GlobeNewswire Jun 6 ...

Mankind Pharma partners with Takeda to introduce Vonoprazan for GERD, oesophagitis, ulcers, and Helicobacter pylori in India. EVP Ramesh stresses business growth. Collaborations with AstraZeneca ...

Earlier this month, Torrent Pharmaceuticals , opens new tab also partnered, opens new tab with Takeda to commercialize Vonoprazan in India. Sun Pharmaceutical's shares rose 0.7% on Friday, while ...

FLORHAM PARK, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...